Inflammation as Prognostic Hallmark of Clinical Outcome in Patients with SARS-CoV-2 Infection DOI Creative Commons

Diana Fuzio,

Angelo Michele Inchingolo, Vitalba Ruggieri

и другие.

Life, Год журнала: 2023, Номер 13(2), С. 322 - 322

Опубликована: Янв. 23, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is often characterized by a life-threatening interstitial pneumonia requiring hospitalization. The aim of this retrospective cohort study to identify hallmarks in-hospital mortality in patients affected Coronavirus Disease 19 (COVID-19). A total 150 admitted for COVID-19 from March June 2021 “F. Perinei” Murgia Hospital Altamura, Italy, were divided into survivors (n = 100) and non-survivors groups 50). Blood counts, inflammation-related biomarkers lymphocyte subsets analyzed two the first 24 h after admission compared Student’s t-test. multivariable logistic analysis was performed independent risk factors associated with mortality. Total count CD3+ CD4+ CD8+ T significantly lower non-survivors. Serum levels interleukin-6 (IL-6), lactate dehydrogenase (LDH), C-reactive protein (CRP) procalcitonin (PCT) higher Age > 65 years presence comorbidities identified as mortality, while IL-6 LDH showed borderline significance. According our results, markers inflammation lymphocytopenia predict COVID-19.

Язык: Английский

Development of SARS-CoV-2 entry antivirals DOI Creative Commons
Meiyue Dong, Jazmin Galván Achi, Ruikun Du

и другие.

Cell Insight, Год журнала: 2024, Номер 3(1), С. 100144 - 100144

Опубликована: Янв. 30, 2024

The global outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatened human health and public safety. development anti-SARS-CoV-2 therapies have been essential to curb spread SARS-CoV-2. Particularly, antivirals targeting viral entry become an attractive target for therapies. In this review, we elucidate mechanism SARS-CoV-2 summarize antiviral inhibitors entry. Moreover, speculate upon future directions toward more potent This study is expected provide novel insights efficient discovery promising candidate drugs against SARS-CoV-2, contribute broad-spectrum anti-coronavirus drugs.

Язык: Английский

Процитировано

8

A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors DOI Creative Commons
Desh Deepak Singh, Ihn Han, Eun Ha Choi

и другие.

Current Issues in Molecular Biology, Год журнала: 2023, Номер 45(1), С. 400 - 433

Опубликована: Янв. 4, 2023

SARS-CoV-2 (severe acute respiratory syndrome) is highly infectious and causes severe distress syndrome (SARD), immune suppression, multi-organ failure. For SARS-CoV-2, only supportive treatment options are available, such as oxygen therapy, ventilator support, antibiotics for secondary infections, mineral fluid treatment, a significant subset of repurposed effective drugs. Viral targeted inhibitors the most suitable molecules, ACE2 (angiotensin-converting enzyme-2) RBD (receptor-binding domain) protein-based inhibitors, host proteases, viral proteases 3CLpro (3C-like proteinase) PLpro (papain-like protease), replicative enzymes, attachment to receptor TMPRSS2 (transmembrane serine proteinase 2), HR1 (Heptad Repeat 1)–HR2 2) interaction at S2 protein coronavirus, etc. Targeting cathepsin L proteinase, peptide analogues, monoclonal antibodies, chimaeras interferes with spike protein’s ability fuse membrane. Even tremendous progress made, creating drugs remains difficult. To develop COVID-19 alternatives, clinical studies examining variety therapy categories, including antivirals, cell-based diagnostic medicines, more. In this article, we discuss recent updates on infection, characteristics, diagnosis, immunopathology, new emergence variant, various approaches drug development options. The therapies has been complicated by global occurrence many mutations. Discussion manuscript will provide insight into pathophysiology development.

Язык: Английский

Процитировано

7

Inflammation as Prognostic Hallmark of Clinical Outcome in Patients with SARS-CoV-2 Infection DOI Creative Commons

Diana Fuzio,

Angelo Michele Inchingolo, Vitalba Ruggieri

и другие.

Life, Год журнала: 2023, Номер 13(2), С. 322 - 322

Опубликована: Янв. 23, 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is often characterized by a life-threatening interstitial pneumonia requiring hospitalization. The aim of this retrospective cohort study to identify hallmarks in-hospital mortality in patients affected Coronavirus Disease 19 (COVID-19). A total 150 admitted for COVID-19 from March June 2021 “F. Perinei” Murgia Hospital Altamura, Italy, were divided into survivors (n = 100) and non-survivors groups 50). Blood counts, inflammation-related biomarkers lymphocyte subsets analyzed two the first 24 h after admission compared Student’s t-test. multivariable logistic analysis was performed independent risk factors associated with mortality. Total count CD3+ CD4+ CD8+ T significantly lower non-survivors. Serum levels interleukin-6 (IL-6), lactate dehydrogenase (LDH), C-reactive protein (CRP) procalcitonin (PCT) higher Age > 65 years presence comorbidities identified as mortality, while IL-6 LDH showed borderline significance. According our results, markers inflammation lymphocytopenia predict COVID-19.

Язык: Английский

Процитировано

5